Private equity firms poised to bid for Sandoz takeover

Generics and biosimilars Initiative

Building trust in cost-effective treatments

Sign up
eng / esp

Private equity firms poised to bid for Sandoz takeover

Home/Pharma News | Posted 25/03/2022 0 Post your comment

Following the late 2021 reports that Novartis is considering a possible sale or spinoff of its generics (and biosimilars) unit, Sandoz [1, 2], two private equity firms are now reportedly discussing a joint bid for the unit.

Blackstone and Carlyle Group are reportedly keen to pair up and bid for Sandoz which could be valued at US$25 billion. This interest in the takeover of Sandoz was sparked when the company revealed that they were carrying out a strategic review of the unit due to reduced Sandoz product sales in the US. This is due to conclude at the end of 2022 [1].

This news comes following a recent announcement that the Swiss Social Democratic party are also interested in the purchase and nationalization of the generics unit [2]. Novartis has also hinted that they are aware of other interest in the purchase of Sandoz.

Should Novartis choose to separate from Sandoz, it will follow in the footsteps of Merck’s Organon, a global healthcare company formed through a spinoff from Merck, which has a primary focus of improving the health of women throughout their lives [1].

LATIN AMERICAN FORUM The new section of the ‘Latin American Forum’ on GaBI has been launched. The objective of this new section is to provide you with all the latest news and updates on developments of generic and biosimilar medicines in Latin America in Spanish. View last week’s headline article: Nomenclatura de biológicos y biocomparables en México Browse the news in the Latin American Forum! Register to receive the GaBI Latin American Forum newsletter. Inform colleagues and friends of this new initiative. LATIN AMERICAN FORUM Se ha lanzado la nueva sección del ‘Foro Latinoamericano’ sobre GaBI. El objetivo de esta nueva sección es brindarle las últimas noticias y actualizaciones sobre desarrollos de medicamentos genéricos y biosimilares en América Latina en español. Vea el artículo principal de la semana pasada: Nomenclatura de biológicos y biocomparables en México !Explore las noticias en el Foro Latinoamericano! Regístrese para recibir el boletín informativo GaBI Foro Latinoamericano. Informe a colegas y amigos sobre esta nueva iniciativa.

References
1. GaBI Online - Generics and Biosimilars Initiative. Spinoff updates Merck’s Organon and Novartis’ Sandoz [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2022 Mar 25]. Available from: www.gabionline.net/pharma-news/spinoff-updates-merck-s-organon-and-novartis-sandoz
2. GaBI Online - Generics and Biosimilars Initiative. Swiss Social Democrat’s for nationalization of Sandoz [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2022 Mar 25]. Available from: www.gabionline.net/pharma-news/swiss-social-democrat-s-for-nationalization-of-sandoz

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.